We have developed a method to remove the lgG and lgM antibodies that cause unwanted intrinsic killing while maintaining sufficient complement potency. Beginning with small lots of a few hundred milliliters, we found that the product worked in a variety of applications and we successfully scaled our process to 1 L+ lots in late 2018. Now our antibody-depleted human complement is available for use in vaccine efficacy programs in volumes sufficient to support clinical trials for many years.
This commercial source of human complement has enabled vaccine developers worldwide to reallocate their time and resources previously spent on making small quantities of human complement to new vaccine discoveries.
